Characteristic | Number of trials (N = 51) |
---|---|
Publication year | Â |
2008 | 12 (24Â %) |
2009 | 11 (22Â %) |
2010 | 7 (14Â %) |
2011 | 4 (9Â %) |
2012 | 8 (16Â %) |
2013 | 9 (18Â %) |
Journals | Â |
Rheumatology journals | Â |
Annals of the Rheumatic Diseases | 19 (37Â %) |
Arthritis & Rheumatism | 17 (33Â %) |
Rheumatology | 5 (10Â %) |
Arthritis Research & Therapy | 1 (2Â %) |
General medical journals | Â |
Lancet | 7 (14Â %) |
New England Journal of Medicine (NEMJ) | 2 (4Â %) |
British Medical Journal (BMJ) | 0 (0Â %) |
Journal of the American Medical Association (JAMA) | 0 (0Â %) |
Funding | Â |
Pharmaceuticals | 47 (92Â %) |
Academic/charity | 4 (8Â %) |
Subjects | Â |
Randomised subjects per trial, median (IQR) | 159 (102–249) |
Mean age in years, median (IQR) | 52 (50–54) |
Mean disease duration in years, median (IQR) | 7.6 (2.3–9.1) |
Follow-up time in weeks, median (IQR) | 24 (14–26) |
12–23 weeks | 14 (27 %) |
24Â weeks | 24 (47Â %) |
>24Â weeks | 13 (26Â %) |